IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on July 1, 2009
(Investigative Ophthalmology and Visual Science. )
© 2009 by The Association for Research in Vision and Ophthalmology, Inc.
doi:10.1167/iovs.08-3201

This Article
Right arrow Full Text (P<P[PDF])
Right arrow All Versions of this Article:
iovs.08-3201v1
50/7/3176    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaye, S. B.
Right arrow Articles by Smith, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaye, S. B.
Right arrow Articles by Smith, G.

Article

Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea

Stephen B. Kaye 1*, Timothy Neal 2, Steven Nicholson 3, Jagoda Szkurlat 3, Sharon Bamber 2, Andrew Baddon 3, Sarah Anderson 3, Keeley Seddon 2, Nichola Dwyer 2, Andrew Lovering 4, and Godfrey Smith 2

1 Medical Microbiology, Royal Liverpool University Hospital, Liverpool, United Kingdom; St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
2 Medical Microbiology, Royal Liverpool University Hospital, Liverpool, United Kingdom
3 St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
4 Centre for Antimicrobial Research and Evaluation, North Bristol NHS Trust, Bristol, United Kingdom

* To whom correspondence should be addressed. E-mail: s.b.kaye{at}liverpool.ac.uk.


   Abstract

Purpose. To investigate the concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea. Method. A biological assay was developed using corneal tissue as a carrier for the antimicrobial. Concentration and biological activity were determined using a chemical assay and zone of inhibition (ZOI) around corneal samples with epithelial and endothelial surfaces in contact with indicator organism. Patients undergoing penetrating keratoplasty received ciprofloxacin 0.3% or teicoplanin 1%. Results. There were good correlations between antimicrobial concentration and ZOI, using filter paper and corneal discs (R2 > 92%). Of 33 patients, mean (median) concentration of ciprofloxacin in the cornea was 1.37 mg/L (0.46 mg/L) and 1.89mg/L (1.44 mg/L) (bioassay) epithelial and endothelial orientations, and 14.87mg/L (7.41) in the cornea and 0.51 mg/L (0.42) in the aqueous (chemical assay). For teicoplanin, mean (median) concentration in the cornea was 9.58 mg/L (0 mg/L) epithelial and 4.78 mg/L (0 mg/L) (bioassay) endothelial orientations. Using a chemical assay teicoplanin could not be detected in the cornea or aqueous at lower limit of detection of 3.6mg/L. Conclusion. The ZOI produced by corneal tissue provides a potential bioassay of antimicrobial activity and concentration. Although in contrast to teicoplanin ciprofloxacin shows good corneal penetration, with high endothelial to epithelial levels, only approximately 10% of measured levels using a chemical assay are available using a bioassay. Teicoplanin shows relatively poor corneal penetration through an intact epithelium. These methods may be useful to evaluate biological activity across the cornea of antimicrobials introduced into ophthalmic practise to deal with changing bacteria resistance.

Key Words: antibiotics, corneal ulceration, pharmacokinetics




This article has been cited by other articles:


Home page
IOVSHome page
S. Kaye, S. Tuft, T. Neal, D. Tole, J. Leeming, F. Figueiredo, M. Armstrong, P. McDonnell, A. Tullo, and C. Parry
Bacterial Susceptibility to Topical Antimicrobials and Clinical Outcome in Bacterial Keratitis
Invest. Ophthalmol. Vis. Sci., January 1, 2010; 51(1): 362 - 368.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the Association for Research in Vision and Ophthalmology